A quarter in cost-recovery limbo; HFC-32 is the step-change

The headline says revenue is growing, the bottom line says it isn't. TANFAC's Q1 results expose a structural gap: top-line recovered to 6.3% YoY growth (driven by solar grade DHF ramp and pricing), but net profit fell 12.9% as input costs—sulphur spiked from ₹30 to ₹105 per unit, power surged—compressed margins faster than the company could pass them through. Management's explanation is sound. But Q1's delivered results don't yet show the cost recovery working.

EBITDA margin held at 15.3% (flat YoY), well within prior guidance of 15–18%. But EBITDA is gross of fixed costs and finance charges. Below-the-line, the hit compounds: geopolitical sulphur spike to ₹105, elevated power and fuel costs (partly driven by captive power plant maintenance downtime), and a deferred tax adjustment all flow to PAT. Management disclosed a 30–45 day cost pass-through lag—contracts repriced monthly or quarterly, not instantaneously. In Q1, that lag appears unresolved: the 15.3% EBITDA margin vs. 9.0% net margin widens to a 6.3 percentage point drag, versus 5.9pp in Q1 FY26. The gap suggests cost recovery has not yet materialized in the delivered quarter.

Beneath Q1's cost headwind sits a transformational capex cycle. HFC-32 (refrigerant R-32, low-GWP replacement for legacy coolants) is 60% built, commissioning by Nov–Dec 2026. Management has pre-contracted 65% of capacity for 5–7 years on take-or-pay terms: 2 firm contracts (Japanese customer, domestic OEM) + 1 MoU converting imminently. The facility targets ~30% EBITDA margin vs. existing business 16–20%, making it the growth engine for FY27 onwards. Revenue potential: ₹900–1,000 Cr annually at full run. FY27 guidance targets 30% blended revenue growth (R-32 Q4 ramp + solar DHF continued push); FY28 targets 60%+ growth once R-32 hits 80–85% utilization. By FY28, blended EBITDA margin reaches ~25%—the margin uplift this quarter is waiting for.

Solar grade DHF (both phases commissioned, 85% contracted) is a structural moat: the 10 parts-per-billion impurity spec creates barriers (capex, 4–5 month learning curve, lengthy customer approvals). TANFAC is India's sole producer today. Tailwind is 6–8x domestic solar wafer/chip capacity growth (35 GW → 210 GW by FY29), driving proportionate DHF demand. AHF (commercial hydrofluoric acid) faces interim headwind: R-32 launch diverts 15,000 MT of 30,000 MT HF capacity to internal use, cutting external AHF sales from ~₹75 Cr to ~₹35–40 Cr. But ₹120 Cr AHF expansion capex (starting post-R-32 commissioning, 12–15 month lag) replaces lost volume. E-chem (electronic grade AHF for semiconductor fabs) is a greenfield play: 1–1.5 year approval cycle, tech tie-up under evaluation, 100 PPT impurity (1,000x harder than solar grade). Revenue potential long-term is significant; timeline uncertain.

The stock was ₹2,720 closing the day before results. Day-1 post-announcement fell 4.41% on the profit miss. But by day 3 (+2.6%) and day 5 (+12.71%), the market recovered sharply—suggesting institutional re-entry as the long-term thesis (R-32 catalysts, margin recovery, capex roadmap) sank in. Current price ₹3,065.7 sits just 1.74% below its all-time high, in overbought territory (RSI 79.7). The stock has rallied 87.78% from its 52-week low. Volume trend is normal, not hyperactive.

Ownership is promoter-heavy: 51.81% promoter (unchanged), 0.03% FII, 0.33% DII. Institutional ownership is minimal; no recent FII/DII buying. The day-5 recovery suggests retail / domestic HNI re-engagement, not institutional conviction. A stock near all-time highs on minimal institutional backing and overbought technicals is vulnerable to a pullback on any stumble (missed cost pass-through in Q2, HFC-32 delay, sulphur spike renewed).

The honest read: This is a steady-execution story with a transformational capex step-change. Q1 is a transition quarter—cost headwinds peak, margin compression visible, but top-line fundamentals (solar DHF ramp, R-32 pre-contracted, pricing power) remain intact. The real earnings inflection comes in H2 FY27 (cost pass-through materializes, R-32 launches) and FY28 (full R-32 ramp, margin recovery to 25%). Execution risk is material (HFC-32 schedule, cost recovery timing, MoU conversion); the day-5 rally suggests the market is pricing in success. At ₹3,065.7, near all-time highs with overbought technicals and minimal institutional backing, the risk-reward is balanced. Holders should track Q2's cost pass-through visibility; new entrants should wait for evidence Q2 PAT recovers.